Seeking cash to fund PhIII for once-failed drug, Adynxx rides Alliqua's shell to Nasdaq
When Adynxx conceded that its non-opioid pain drug failed in Phase II, it vowed to hold out for a Phase III where it would focus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
